Results from phase IIb/III trial suggest benefit from intravenous aviptadil (RLF-100) in critically ill COVID-19 patients

In this study (n=196) 75% of those receiving RLF-100 (a synthetic formulation of naturally occurring vasoactive intestinal polypeptide) successfully recovered vs 55% on placebo, two months after treatment. Additionally, 84% of patients on RLF-100 survived, vs 60% on the placebo.